• 1
    Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:20920.
  • 2
    Marlar RA. Are laboratory results (phenotype) indicative of a true genotype abnormality? Am J Clin Pathol 2012;137:1735.
  • 3
    Adcock DM. Sample integrity and preanalytical variables. In: Quality in Laboratory Hemostasis and Thrombosis. Kitchen S, Olson JD, Preston FE (eds). Chichester, UK: Wiley-Blackwell; 2009: 3142.
  • 4
    CLSI. Collection, Transport and Processing of Blood Specimens for Testing Plasma based coagulation assays and Molecular Haemostasis assays: Approved Guideline, 5th edn. Wayne, PA: CLSI; 2008: H21A5.
  • 5
    Lippi G, Blanckaert N, Bonini P, Green S, Kitchen S, Palicka V, Vassault AJ, Plebani M. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008;46:76472.
  • 6
    CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline, 3rd edn. Wayne, PA: Clinical and Laboratory Standards Institute: document; 2008; C28A3.
  • 7
    Marlar RA. Hemostasis Test Validation, Performance and Reference Intervals. Chapter 2. In: Quality in Laboratory Hemostasis and Thrombosis, 2nd edn. Olson J, Kitchen S, Preston E (eds). Hoboken, NJ: Blackwell Publishers, 2013: 1221.
  • 8
    Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992;80:19982005.
  • 9
    Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001;113:63641.
  • 10
    Marlar RA, Gausman JN. Protein S abnormalities: a diagnostic nightmare. Am J Hematol 2011;86:41821.
  • 11
    Walker ID, Greaves M, Preston FE; Haemostasis and Thrombosis Task Force; British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. J Clin Ligand Assay 2001;114:51228.
  • 12
    Chalmers E, Cooper P, Forman K, Grimley C, Khair K, Minford A, Morgan M, Mumford A. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child 2011;96:106671.
  • 13
    Marlar RA, Adcock DM, Madden RM. Hereditary dysfunctional protein C molecules (Type II): assay characterization and proposed classification. Thromb Haemost 1990;63:3759.
  • 14
    Cooper PC, Siddiq S, Morse C, Nightingale J, Mumford AD. Marked discrepancy between coagulometric Protein C activity assays with the pro-thrombotic Protein C Asn2Ile substitution. Int J Lab Hematol 2011;33:4516.
  • 15
    Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M. British Committee for Standards in Hematology. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 2013;35:113.
  • 16
    Stocker K, Fischer H, Meier J, Brogli M, Svendsed C. Protein C activators in snake venoms. Behring Inst Mitt 1986;79:3747.
  • 17
    D'Angelo SV, Gilardoni F, D'Angelo A. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S. Thromb Haemost 1989;62:8617.
  • 18
    Makris M, Leach M, Beauchamp NJ, Daly ME, Cooper PC, Hampton KK, Bayliss P, Peake IR, Miller GJ, Preston FE. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000;95:193541.
  • 19
    Marlar RA, Potts RM, Welsh CW. Accuracy of diagnosis of protein S deficiency by protein S activity and antigen assays. J Clin Ligand 2005;28:1305.
  • 20
    Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b binding protein during pregnancy and oral contraception. Br J Haematol 1988;68:43743.
  • 21
    Patnaik MM, Moll S. Inherited antithrombin deficiency. Haemophilia 2008;14:122939.
  • 22
    Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, Ofosu FA, Fernandez-Rachubinski F, Andrew M, Hirsh J, Ginsberg JS. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993;69:2315.
  • 23
    Tran Tri H, Duckert F. Influence of heparin cofactor II (HCII) on the determination of antithrombin III (AT). Thromb Res 1985;40:5716.
  • 24
    Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blomback M. Discrepancy between antithrombin activity methods revealed in antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 1992;99:22712.
  • 25
    Kristensen SR, Rasmussen B, Pedersen S, Bathum L. Detecting antithrombin deficiency may be a difficult task–more than one test is necessary. J Thromb Haemost 2007;5:6178.
  • 26
    Harper PL, Daly M, Price J, Edgar PF, Carrell RW. Screening for heparin binding variants of antithrombin. J Clin Pathol 1991;44:4779.